Eczema

2 stories across channels

#20

Apogee Therapeutics: Zumilokibart Phase 2 Shows 75-85% Maintain EASI-75 at One Year With Quarterly or Semi-Annual Dosing

Apogee Therapeutics announced positive 52-week Phase 2 Part A data for zumilokibart (APG777) in moderate-to-severe atopic dermatitis. In the APEX trial, 75% of patients on quarterly injections and 85% on semi-annual injections maintained at least EASI-75 (75% improvement in skin lesion severity) at one year. These maintenance rates are comparable to Dupixent and Ebglyss but with dramatically less frequent dosing — every 3-6 months versus monthly alternatives. Phase 3 trials are expected to begin in the second half of 2026.

The Frontier Desk · Monday, March 23, 2026

#21

Mount Sinai Publishes First Organ-Wide Human Skin Spatial Atlas in Nature Genetics — 1.2M Cells Mapped Across 45 Types

Mount Sinai researchers published a landmark study in Nature Genetics mapping 1.2 million cells across 15 anatomic sites from 22 donors, identifying 45 unique cell types and their spatial organization into 'multicellular neighborhoods.' The atlas reveals how these neighborhoods are disrupted in skin diseases including eczema and psoriasis. Perivascular neighborhoods — clusters of immune cells and fibroblasts around blood vessels — were identified as key sites of disease disruption, suggesting new therapeutic targets.

The Frontier Desk · Monday, March 23, 2026